Anti-Potassium Channel ERG1 Antibody, CT

ERG1 encodes the pore forming alpha subunit of the voltage-gated channels that conduct the rapid delayed rectifier potassium current, which leads to termination of the cardiac ventricular action potential. A large number of commercially available therapeutic agents (antiarrhythmics, antihistamines, antibiotics and antidepressants) have been shown to preferentially block ERG1 and cause a disorder of cardiac action potential depolarization that predisposes affected individuals to ventricular arrhythmia and sudden death.

ERG1 protein. By western blot, antibody recognizes bands at 175 and 205 kDa (glycosylated) or 135 and 165 kDa (deglycosylated).

Epitope: C-terminus

Synthetic peptide corresponding to the C-terminus of ERG1 (aa 1145-1159 of HERG1).

Anti-Potassium Channel ERG1 Antibody, C-terminus detects level of Potassium Channel ERG1 & has been published & validated for use in IC, IH, IP & WB.

Immunoblotting: 5 μg/mL

Immunocytochemistry

Immunohistochemistry on 4% paraformaldehyde fixed tissues.

Immunoprecipitation

Optimal working dilutions must be determined by end user.

Research Category
Neuroscience

Research Sub Category
Ion Channels & Transporters

Liquid in PBS with 0.1% sodium azide.

Maintain at 2-8°C in undiluted aliquots for up to 6 months after date of receipt. Avoid repeated freeze/thaw cycles

Control
Positive control tissue: Heart

Concentration: Please refer to the Certificate of Analysis for the lot-specific concentration.

CHEMICON is a registered trademark of Merck KGaA, Darmstadt, Germany

Unless otherwise stated in our catalog or other company documentation accompanying the product(s), our products are intended for research use only and are not to be used for any other purpose, which includes but is not limited to, unauthorized commercial uses, in vitro diagnostic uses, ex vivo or in vivo therapeutic uses or any type of consumption or application to humans or animals.